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Maria José Passos2
1Department of Medical Oncology, Hospital Professor Doutor Fernando Fonseca E.P.E., 2720-276 Amadora, Portugal
2Department of Medical Oncology, Instituto Português de Oncologia de Lisboa, Francisco Gentil E.P.E., 1099-023 Lisboa, Portugal
3Department of Ophthalmology, Centro Hospitalar Lisboa Central E.P.E., 1150-199 Lisboa, Portugal
Correspondence should be addressed to Simão Pinto Torres; simaoptorres@gmail.com
Received 12 June 2017; Accepted 18 September 2017; Published 26 October 2017
Academic Editor: Constantine Gennatas
Copyright © 2017 Simão Pinto Torres et al. (is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conjunctival melanoma (CM) is an exceptionally rare tumor, with a propensity for local and distant recurrence, with the lungs,
skin, liver, and brain being the most common sites of metastasis. Recent progress in systemic treatments, with checkpoint
inhibitors and targeted therapies blocking BRAF and MEK, has rede6ned the standard of care of advanced unresectable and
metastatic melanoma. Although most trials did not include patients with conjunctival melanoma, its close molecular and genetic
relationship to cutaneous melanoma might suggest a similar response to these novel agents. (e authors describe two uncommon
cases of metastatic conjunctival melanomas with distinct genetic pro6les and, as such, submitted to di7erent systemic treatments.
1. Introduction
Conjunctival melanoma (CM) is a rare tumor, with an in-
cidence of 0.02 to 0.08 per 100,000 in white populations. It
accounts for 1% to 3% of all ocular malignancies in adults
and represents only 1.6% of all noncutaneous melanomas in
published series, with increasing incidence in the elderly [1].
CM usually develops within the bulbar conjunctiva,
rather than the forniceal or palpebral conjunctiva, and can
arise in areas of primary acquired melanosis, from a pre-
existing nevus or de novo [2].
CM is an aggressive tumor, with a propensity for local
and distant recurrence [3].
Pathological features recognized as predictive of poor
survival and locoregional recurrence are tumor thickness,
nonepibulbar locations, and multifocal CM.
In addition to spreading by lymphatics and the blood-
stream, CM can undergo direct extension to the globe and
orbit [4].
(e most common sites of metastasis are the lungs, skin,
liver, and brain.
Although a historically treatment-refractory disease,
recent progress in systemic treatments, with important
bene6ts in disease control and survival, has rede6ned the
standard of care of advanced unresectable and metastatic
melanoma [5].
2. Case Presentation 1 (Patient 1)
A 56-year-old Caucasian woman presented with a pig-
mented lesion developing on a preexisting pterygium of the
right eye, with gradual growth since October 2007. Complete
excisional biopsy was performed in March 2010, showing
a malignant melanoma of the bulbar conjunctiva, with
1.9mm in thickness.
(e patient was lost to follow-up until July 2013, when
she turned to the hospital after developing nasal obstruction
and fatigue. Laryngoscopy and head MRI revealed a pe-
dunculated mass on the right oropharyngeal wall, with
31 ×13mm in diameter.
(e mass was surgically removed, with a thorough
pathologic assessment revealing an ulcerated metastasis of
a conjunctival melanoma, with 6.5mm in thickness and no
subepithelial component.
A staging PET/CT scan showed multiple pharyngeal
lymphadenopathies.
(e patient was referred to our institution for further
management, with the abovementioned 6ndings being
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con6rmed. A mutation in exon 15 of the BRAF gene (V600)
was detected by Cobas 4800.
Two months after surgery, there was evidence of local
recurrence with symptoms reappearing, and a body PET/CT
scan showed a de novo endophytic mass, with 31×22mm,
on the previously a7ected location (Figure 1(a)).
(e lesion was considered unresectable, and palliative
external radiotherapy, with a total dose of 20Gy/5 fr, was
performed.
In April 2014, systemic therapy was initiated with
vemurafenib (960mg) twice a day.
After one month of therapy, there was full symptomatic
resolution.
Restaging evaluation showed sustained favorable re-
sponse, resulting in complete remission (Figure 1(b)).
(ere was a need for dose reduction to 480mg twice
a day because of grade 2 arthralgia, grade 2 diarrhea, and
grade 1 skin rash.
In February 2017, she was diagnosed with early stage,
grade 2, invasive ductal carcinoma of the left breast,
pT1cN0snM0, with estrogen receptors +100%, progesterone
receptors +1%, HER2 1+, and Ki67 +15%.
She was submitted to a left simple mastectomy with
sentinel lymph node biopsy and began hormonal treatment
with tamoxifen (20mg) once a day.
(e patient remains free of new lesions as of the last
follow-up, on August 8, 2017.
3. Case Presentation 2 (Patient 2)
A 51-year-old Caucasian man had a remote history of
human immunode6ciency virus (HIV) and hepatitis C virus
(HCV) infections, medicated with antiretroviral therapy,
with a CD4 count within the normal range and an un-
detectable viral load. In December 2009, he presented with
a hyperpigmented lesion on the temporal conjunctiva of the
right eye. Excisional biopsy showed a compound melano-
cytic nevus.
In December 2011, the lesion recurred on the temporal,
inferior, and nasal conjunctiva.
Surgical excision revealed a completely excised malig-
nant melanoma of the bulbar conjunctiva, with 2.4mm in
thickness.
One year later, he was reintervened for a second re-
currence on the inferior and temporal conjunctiva.
He was maintained under active surveillance until July
2016, when right cervical adenopathies were noted. Exci-
sional biopsy con6rmed metastases of malignant melanoma
positive for S100 and MELAN A and negative for CAM 5.2.
(e patient was then referred to our institution for further
management, with pathologic reevaluation con6rming the
diagnosis. No mutation in the BRAF gene was detected.
A body PET/CT scan documented cervical, sub-
mandibular, and pharyngeal adenopathies.
He was submitted to a right cervical lymphadenectomy,
with metastases in 6ve of the thirty lymph nodes removed.
Subsequent radiotherapy was initially planned; however,
within three weeks, there was rapid disease progression, with
multiple de novo subcutaneous nodes of the face and neck.
In December 2016, systemic therapy was initiated with
pembrolizumab (2mg/kg) every 3 weeks.
After the third cycle, there was near to complete reso-
lution of the subcutaneous lesions.
At the last follow-up, on August 23, 2017, the patient was
on complete remission, with good tolerance to the ongoing
treatment.
4. Discussion
We describe two seldom cases of metastatic conjunctival
melanomas with distinct genetic pro6les and, as such,
submitted to di7erent systemic treatments. Both patients
have sustained favorable responses up until the writing of
this article.
Advances in systemic treatments, with an important
enhancement in disease control and survival, have recently
changed the standard of care of advanced unresectable and
metastatic melanoma [5]. Immunotherapy with checkpoint
inhibitors and targeted therapies blocking BRAF and MEK
demonstrated signi6cantly improved outcomes compared with
conventional therapies [5, 6]. BRAF and MEK inhibitors
are indicated for approximately 50% of patients who harbor
(a)
(b)
Figure 1: Changes in tumor size in patient 1. A CTscan of the neck,
performed at the time of the second recurrence, showing an en-
dophytic mass, with 3.1×2.2 cm, on the right oropharyngeal wall,
with reduction of its caliber (a). Recent reevaluation showing
sustained complete response to vemurafenib, 34 months after
starting the treatment (b).
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the BRAF V600 mutations, while programmed death-1
(PD-1) inhibitors are e7ective regardless of BRAF mu-
tational status [6–14].
Although most trials did not include patients with
conjunctival melanoma, its close molecular and genetic
relationship to cutaneous melanoma might suggest a similar
response to these novel agents [8]. Griewank et al. [9]
identi6ed BRAF mutations in 23 of 78 (29%) conjunctival
melanomas, a majority of which (91%) were V600E
mutations.
In case 1, when the patient began treatment, single-agent
therapy with vemurafenib or dabrafenib was the standard of
care. Although the combination with BRAF and MEK in-
hibitors proved to have less toxicity and to be more e7ective
regarding response rates, progression-free survival, and
overall survival, it only became available in our country
posteriorly [10, 11].
Despite the known risk of the emergence of resistance
[12, 13], given the patient’s prolonged complete response, the
authors opted to maintain single-agent BRAF inhibitor
therapy.
Her recent diagnosis of breast cancer raises the question
whether the disease can be related to prolonged treatment
with vemurafenib.
Secondary tumors, like cutaneous squamous cell carci-
nomas or keratoacanthoma, can occur in approximately 25%
of patients treated with vemurafenib, as a result of para-
doxical activation of the mitogen-activated protein kinase
pathway in nonmelanoma BRAF wild-type cells [14].
Novik et al. [15] reported a relapse of breast cancer after
initiating vemurafenib in a patient with BRAF-mutated
cutaneous melanoma.
At the present time, however, there are insuNcient data
to make this assumption.
In case 2, there were concerns about the use of a check-
point inhibitor in a patient with HIV, given there could be
immune-related side e7ects speci6c to this population.
(ere is scarce literature regarding this issue. As this is
a generalized concern, these patients are usually excluded
from trials with immunotherapy.
Davar et al. [16] reported two cases with advanced cu-
taneous melanoma and concomitant HCV and HIV in-
fections treated with pembrolizumab, with good tolerance
and without exacerbation of the underlying infection.
(e same was observed in our patient, with treatment
proving to be e7ective and excellently tolerated.
In conclusion, both treatments, with BRAF inhibitors
(in the presence of the BRAF gene mutation) and PD-1
inhibitors, seem to be valid options in the treatment of
metastatic conjunctival melanoma.
Prospective studies are needed to further con6rm the
eNcacy and tolerability of these treatments in this patient
population.
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